First-in-Human Percutaneous Circumferential Annuloplasty for Secondary Tricuspid Regurgitation

Reddy, Vivek Y.; Abbo, Aharon; Ruiz, Carlos E.; Kerner, Arthur; Kreidel, Felix; Kipshidze, N N; Avisar, Noa; Petrů, Jan; Neužil, Petr

doi:10.1016/j.jaccas.2020.08.032

Cited by 11 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The MIA™-T system (Micro Interventional Devices, Newtown, PA, USA), a sutureless transcatheter annuloplasty system, is being investigated in a study (STTAR study) using both the surgical and transcatheter approach. Furthermore, successful implantation of a two-stage percutaneous annuloplasty system (Cardiac Implant LLC, Tarrytown, NY, USA) was reported in 2020 75 .…”

Section: Leaflet Approximationmentioning

confidence: 99%

Transcatheter treatment for tricuspid valve disease

Praz¹,

Muraru²,

Kreidel³

et al. 2021

EuroIntervention

Self Cite

210

129

View full text Add to dashboard Cite

Section: Leaflet Approximationmentioning

confidence: 99%

Transcatheter treatment for tricuspid valve disease

Praz¹,

Muraru²,

Kreidel³

et al. 2021

EuroIntervention

Self Cite

210

129

View full text Add to dashboard Cite

“…An adjustment connector is left fixed to the jugular vein and, 3 months later when the ring has healed, a second procedure is done to contract the annular ring size. This study is still recruiting with successful first-in-human experience published (60). Transatrial intrapericardial tricuspid annuloplasty (TRAIPTA) Device and Procedural Aspects.…”

Section: Davingi Tr Systemmentioning

confidence: 99%

New therapeutic approach for tricuspid regurgitation: Transcatheter tricuspid valve replacement or repair

Blusztein

Hahn

2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The tricuspid valve is a complex structure with normal function dependent on the leaflet morphology, right atrial and annular dynamics, and right ventricular and chordal support. Thus, the pathophysiology of tricuspid regurgitation (TR) is equally complex and current medical and surgical management options are limited. Transcatheter devices are currently being investigated as possible treatment options with lower morbidity and mortality than open surgical procedures. These devices can be divided by their implant location/mechanism of action: leaflet approximation devices, annuloplasty devices, orthotopic valve implants, and heterotopic valve implants. The current review will discuss each class of transcatheter device therapy, and further delve into the current understanding of who and when to treat. Finally, we will include a brief discussion of the future of device and surgical therapy trials for TR and the remaining questions to answer about this complex disease process.

show abstract

“…The DaVingi device (Cardiac Implants, Tarrytown, New York) consists of a ring delivery system and an annuloplasty ring. A first-in-human report was recently published ( 34 ), and a first-in-human study, which is planning to include 15 patients, is currently ongoing (NCT03700918).…”

Section: Devices With Clinical Data: Transcatheter Tricuspid Valve Re...mentioning

confidence: 99%

Transcatheter tricuspid valve interventions: Current status and future perspectives

Alperi

Almendárez

Álvarez

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

The development of transcatheter therapies to treat valvular heart diseases has changed the rules of the game, particularly in the case of aortic stenosis and mitral regurgitation. In the last years, the tricuspid valve has also been the focus of these percutaneous techniques for several reasons: (1) tricuspid regurgitation is a frequent disease associated with poor clinical outcomes in spite of medical treatment, leading to end-stage right ventricular heart failure, (2) surgical tricuspid valve repair or replacement has been the treatment of choice for patients with tricuspid valve disease, but high mortality rates for isolated surgical tricuspid valve intervention have been reported in the literature, and (3) most patients with tricuspid pathology are ultimately denied cardiac surgery because of their comorbidity burden. Thus, in this context the development of less invasive catheter-based therapies would be of high clinical relevance. The present review provides an overview regarding the framework of chronic tricuspid regurgitation transcatheter therapeutic options, summarizes the transcatheter systems under clinical use or clinical evaluation with their technical features, and describes the updated current evidence in this challenging and evolving field.

show abstract

First-in-Human Percutaneous Circumferential Annuloplasty for Secondary Tricuspid Regurgitation

Cited by 11 publications

References 8 publications

Transcatheter treatment for tricuspid valve disease

Transcatheter treatment for tricuspid valve disease

New therapeutic approach for tricuspid regurgitation: Transcatheter tricuspid valve replacement or repair

Transcatheter tricuspid valve interventions: Current status and future perspectives

Contact Info

Product

Resources

About